Symbols / MLTX Stock $18.41 +1.21% MoonLake Immunotherapeutics
MLTX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Ratings
Current target
$18.41
Low
$6.00
High
$45.00
Mean
$26.77
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-12 | main | Needham | Buy → Buy | $30 |
| 2026-05-11 | main | HC Wainwright & Co. | Buy → Buy | $45 |
| 2026-03-30 | reit | BTIG | Buy → Buy | $30 |
| 2026-03-23 | up | Wolfe Research | Underperform → Outperform | $24 |
| 2026-03-19 | up | Rothschild & Co | Neutral → Buy | $40 |
| 2026-03-11 | main | Clear Street | Buy → Buy | $70 |
| 2026-03-02 | main | RBC Capital | Sector Perform → Sector Perform | $13 |
| 2026-03-02 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-02-26 | reit | Needham | Buy → Buy | $25 |
| 2026-02-24 | main | Oppenheimer | Outperform → Outperform | $35 |
| 2026-02-23 | main | BTIG | Buy → Buy | $30 |
| 2026-02-23 | main | Needham | Buy → Buy | $25 |
| 2026-02-20 | main | RBC Capital | Sector Perform → Sector Perform | $12 |
| 2026-02-09 | reit | BTIG | Buy → Buy | $24 |
| 2026-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2026-01-15 | down | Goldman Sachs | Neutral → Sell | $10 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2026-01-09 | up | BTIG | Neutral → Buy | $24 |
| 2025-11-21 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-11-03 | up | HC Wainwright & Co. | Neutral → Buy | $30 |
- MoonLake Immunotherapeutics (MLTX) Stock News - Stock Titan Sun, 10 May 2026 13
- MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN hu, 14 May 2026 02
- MLTX Stock Soars Overnight After FDA Backs Skin Drug Filing — Analyst Sees Over 300% Upside On ‘Best-In-Class’ Label - Stocktwits Sun, 10 May 2026 23
- MoonLake (MLTX) Shares Gain After Positive FDA Meeting on Sonelokimab Filing - Yahoo Finance Mon, 11 May 2026 14
- FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars - Benzinga Mon, 11 May 2026 15
- MoonLake Immunotherapeutics (MLTX) CFO logs pre-planned sale of 13,653 shares - Stock Titan Wed, 13 May 2026 20
- MLTX stock soars overnight after FDA backs skin drug filing — analyst sees over 300% upside on 'best-in-class' label - MSN hu, 14 May 2026 02
- MoonLake Immunotherapeutics (MLTX) Is Up 5.0% After FDA Alignment On Sonelokimab BLA Timing And Label Strategy - simplywall.st Mon, 11 May 2026 01
- Experimental HS drug sonelokimab nears FDA filing after key MoonLake meeting - Stock Titan Sun, 10 May 2026 13
- Dow, S&P 500, Nasdaq futures slip as Trump calls Iran’s peace proposal ‘totally unacceptable’ — MU, SNDK, MRAM, MLTX stocks in focus - MSN hu, 14 May 2026 06
- Nasdaq, S&P 500 futures dip as Trump-Iran tensions lift crude oil prices: Why MU, MRAM, MLTX, DRTS, ASTS are in focus - MSN hu, 14 May 2026 00
- The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? - The Motley Fool Sat, 18 Apr 2026 07
- Insider Sale: Chief Executive Officer of $MLTX Sells 51,873 Shares - Quiver Quantitative ue, 14 Apr 2026 07
- Needham raises Moonlake stock price target to $30 on BLA filing plans - Investing.com ue, 12 May 2026 12
- Down-But-Not-Out Biotech Rockets On A Key FDA Decision - Investor's Business Daily Mon, 11 May 2026 20
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
244.83
+71.10%
|
143.09
+164.38%
|
54.12
-16.81%
|
65.06
|
| Research And Development |
|
202.86
+79.89%
|
112.77
+254.60%
|
31.80
-24.37%
|
42.05
|
| Selling General And Administration |
|
41.97
+38.43%
|
30.32
+35.84%
|
22.32
-3.00%
|
23.01
|
| General And Administrative Expense |
|
41.97
+38.43%
|
30.32
+35.84%
|
22.32
-3.00%
|
23.01
|
| Other Gand A |
|
41.97
+38.43%
|
30.32
+35.84%
|
22.32
-3.00%
|
23.01
|
| Total Expenses |
|
244.83
+71.10%
|
143.09
+164.38%
|
54.12
-16.81%
|
65.06
|
| Operating Income |
|
-244.83
-71.10%
|
-143.09
-164.38%
|
-54.12
+16.81%
|
-65.06
|
| Total Operating Income As Reported |
|
-244.83
-71.10%
|
-143.09
-164.38%
|
-54.12
+16.81%
|
-65.06
|
| EBITDA |
|
-219.85
-83.85%
|
-119.58
-174.16%
|
-43.62
+32.79%
|
-64.90
|
| Normalized EBITDA |
|
-219.85
-83.85%
|
-119.58
-174.16%
|
-43.62
+32.79%
|
-64.90
|
| Reconciled Depreciation |
|
2.62
+88.88%
|
1.39
+274.32%
|
0.37
+124.54%
|
0.16
|
| EBIT |
|
-222.46
-83.91%
|
-120.96
-175.01%
|
-43.98
+32.39%
|
-65.06
|
| Net Income |
|
-227.32
-91.13%
|
-118.94
-230.31%
|
-36.01
+27.95%
|
-49.97
|
| Pretax Income |
|
-229.71
-89.90%
|
-120.96
-175.01%
|
-43.98
+31.77%
|
-64.47
|
| Net Non Operating Interest Income Expense |
|
-7.25
|
0.00
|
0.00
|
—
|
| Interest Expense Non Operating |
|
7.25
|
0.00
|
0.00
|
—
|
| Net Interest Income |
|
-7.25
|
0.00
|
0.00
|
—
|
| Interest Expense |
|
7.25
|
0.00
|
0.00
|
—
|
| Other Income Expense |
|
22.37
+1.10%
|
22.13
+118.28%
|
10.14
+1613.28%
|
0.59
|
| Other Non Operating Income Expenses |
|
22.37
+1.10%
|
22.13
+118.28%
|
10.14
+1613.28%
|
0.59
|
| Tax Provision |
|
0.61
+116.67%
|
0.28
+200.00%
|
0.09
+158.48%
|
0.04
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-230.32
-89.96%
|
-121.24
-175.06%
|
-44.08
+31.67%
|
-64.51
|
| Net Income From Continuing Operation Net Minority Interest |
|
-227.32
-91.13%
|
-118.94
-230.31%
|
-36.01
+27.95%
|
-49.97
|
| Net Income From Continuing And Discontinued Operation |
|
-227.32
-91.13%
|
-118.94
-230.31%
|
-36.01
+27.95%
|
-49.97
|
| Net Income Continuous Operations |
|
-230.32
-89.96%
|
-121.24
-175.06%
|
-44.08
+31.67%
|
-64.51
|
| Minority Interests |
|
3.00
+30.11%
|
2.31
-71.41%
|
8.07
-44.46%
|
14.53
|
| Normalized Income |
|
-227.32
-91.13%
|
-118.94
-230.31%
|
-36.01
+27.95%
|
-49.97
|
| Net Income Common Stockholders |
|
-227.32
-91.13%
|
-118.94
-230.31%
|
-36.01
+27.95%
|
-49.97
|
| Diluted EPS |
|
-3.53
-86.77%
|
-1.89
-158.90%
|
-0.73
+43.06%
|
-1.28
|
| Basic EPS |
|
-3.53
-86.77%
|
-1.89
-158.90%
|
-0.73
+43.06%
|
-1.28
|
| Basic Average Shares |
|
64.46
+2.53%
|
62.87
+27.99%
|
49.12
+26.03%
|
38.98
|
| Diluted Average Shares |
|
64.46
+2.53%
|
62.87
+27.99%
|
49.12
+26.03%
|
38.98
|
| Diluted NI Availto Com Stockholders |
|
-227.32
-91.13%
|
-118.94
-230.31%
|
-36.01
+27.95%
|
-49.97
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
526.54
|
| Current Assets |
|
514.17
|
| Cash Cash Equivalents And Short Term Investments |
|
511.01
|
| Cash And Cash Equivalents |
|
451.17
|
| Cash Financial |
|
—
|
| Other Short Term Investments |
|
59.84
|
| Receivables |
|
1.06
|
| Other Receivables |
|
1.06
|
| Prepaid Assets |
|
2.10
|
| Total Non Current Assets |
|
12.37
|
| Net PPE |
|
3.95
|
| Gross PPE |
|
3.95
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
3.63
|
| Other Properties |
|
0.32
|
| Non Current Prepaid Assets |
|
8.42
|
| Other Non Current Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
13.05
|
| Current Liabilities |
|
9.97
|
| Payables And Accrued Expenses |
|
5.99
|
| Payables |
|
2.21
|
| Accounts Payable |
|
1.46
|
| Other Payable |
|
0.37
|
| Current Accrued Expenses |
|
3.78
|
| Employee Benefits |
|
0.58
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.78
|
| Total Tax Payable |
|
0.37
|
| Current Debt And Capital Lease Obligation |
|
1.20
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
1.20
|
| Total Non Current Liabilities Net Minority Interest |
|
3.08
|
| Long Term Debt And Capital Lease Obligation |
|
2.50
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
2.50
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
0.58
|
| Stockholders Equity |
|
495.68
|
| Common Stock Equity |
|
495.68
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
60.47
|
| Ordinary Shares Number |
|
60.47
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
609.97
|
| Retained Earnings |
|
-116.66
|
| Gains Losses Not Affecting Retained Earnings |
|
2.36
|
| Treasury Stock |
|
—
|
| Minority Interest |
|
17.82
|
| Other Equity Adjustments |
|
2.36
|
| Total Equity Gross Minority Interest |
|
513.49
|
| Total Capitalization |
|
495.68
|
| Working Capital |
|
504.20
|
| Invested Capital |
|
495.68
|
| Total Debt |
|
3.70
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
3.70
|
| Net Tangible Assets |
|
495.68
|
| Tangible Book Value |
|
495.68
|
| Preferred Stock Equity |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-196.01
-68.12%
|
-116.59
-172.54%
|
-42.78
+23.47%
|
-55.89
|
| Cash Flow From Continuing Operating Activities |
|
-196.01
-68.12%
|
-116.59
-172.54%
|
-42.78
+23.47%
|
-55.89
|
| Net Income From Continuing Operations |
|
-230.32
-89.96%
|
-121.24
-175.06%
|
-44.08
+31.67%
|
-64.51
|
| Depreciation Amortization Depletion |
|
2.62
+88.88%
|
1.39
+274.32%
|
0.37
+124.54%
|
0.16
|
| Depreciation |
|
—
|
—
|
0.01
+6.47%
|
0.01
|
| Depreciation And Amortization |
|
2.62
+88.88%
|
1.39
+274.32%
|
0.37
+124.54%
|
0.16
|
| Other Non Cash Items |
|
-1.02
-349.34%
|
-0.23
-277.34%
|
0.13
+86.99%
|
0.07
|
| Pension And Employee Benefit Expense |
|
-0.06
-5900.00%
|
0.00
+101.18%
|
-0.09
-127.96%
|
0.30
|
| Stock Based Compensation |
|
12.90
+77.12%
|
7.28
+2.48%
|
7.11
-26.40%
|
9.65
|
| Operating Gains Losses |
|
-0.06
-5900.00%
|
0.00
+101.18%
|
-0.09
-127.96%
|
0.30
|
| Change In Working Capital |
|
19.88
+625.32%
|
-3.78
+39.14%
|
-6.22
-293.57%
|
-1.58
|
| Change In Receivables |
|
-2.02
-13.38%
|
-1.79
-112.62%
|
-0.84
-1128.88%
|
-0.07
|
| Change In Prepaid Assets |
|
0.56
+104.35%
|
-12.89
-103.17%
|
-6.35
-132.42%
|
-2.73
|
| Change In Payables And Accrued Expense |
|
23.15
+87.85%
|
12.32
+881.21%
|
1.26
-8.41%
|
1.37
|
| Change In Accrued Expense |
|
2.59
-49.87%
|
5.17
+1680.73%
|
-0.33
-112.18%
|
2.69
|
| Change In Payable |
|
20.56
+187.35%
|
7.16
+351.99%
|
1.58
+220.44%
|
-1.31
|
| Change In Other Working Capital |
|
—
|
—
|
-0.07
|
—
|
| Change In Other Current Assets |
|
-0.59
-9683.33%
|
-0.01
+90.91%
|
-0.07
|
0.00
|
| Change In Other Current Liabilities |
|
-1.22
+14.13%
|
-1.42
-540.99%
|
-0.22
-45.65%
|
-0.15
|
| Investing Cash Flow |
|
202.99
+198.73%
|
-205.60
-716.38%
|
-25.18
+22.13%
|
-32.34
|
| Cash Flow From Continuing Investing Activities |
|
202.99
+198.73%
|
-205.60
-716.38%
|
-25.18
+22.13%
|
-32.34
|
| Net PPE Purchase And Sale |
|
-0.04
+93.27%
|
-0.52
-83.10%
|
-0.28
-1674.00%
|
-0.02
|
| Purchase Of PPE |
|
-0.04
+93.27%
|
-0.52
-83.10%
|
-0.28
-1674.00%
|
-0.02
|
| Capital Expenditure |
|
-0.04
+93.27%
|
-0.52
-83.10%
|
-0.28
-1674.00%
|
-0.02
|
| Net Investment Purchase And Sale |
|
203.03
+199.00%
|
-205.08
-723.60%
|
-24.90
+22.97%
|
-32.32
|
| Purchase Of Investment |
|
-265.37
+24.24%
|
-350.28
-99.32%
|
-175.73
-316.17%
|
-42.23
|
| Sale Of Investment |
|
468.40
+222.58%
|
145.20
-3.73%
|
150.83
+1423.34%
|
9.90
|
| Financing Cash Flow |
|
146.00
+184.53%
|
51.31
-89.30%
|
479.70
+300.78%
|
119.69
|
| Cash Flow From Continuing Financing Activities |
|
146.00
+184.53%
|
51.31
-89.30%
|
479.70
+300.78%
|
119.69
|
| Net Issuance Payments Of Debt |
|
73.02
|
0.00
|
0.00
+100.00%
|
-15.00
|
| Issuance Of Debt |
|
73.02
|
0.00
|
0.00
|
0.00
|
| Repayment Of Debt |
|
—
|
0.00
|
0.00
+100.00%
|
-15.00
|
| Long Term Debt Issuance |
|
73.02
|
0.00
|
0.00
|
—
|
| Long Term Debt Payments |
|
—
|
0.00
|
0.00
+100.00%
|
-15.00
|
| Net Long Term Debt Issuance |
|
73.02
|
0.00
|
0.00
+100.00%
|
-15.00
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
72.39
+37.79%
|
52.54
-89.11%
|
482.45
|
0.00
|
| Common Stock Payments |
|
—
|
-0.00
|
0.00
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
-0.00
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.58
+139.67%
|
0.24
|
0.00
-100.00%
|
0.00
|
| Net Other Financing Charges |
|
—
|
-1.47
+46.60%
|
-2.75
-102.04%
|
134.69
|
| Changes In Cash |
|
152.98
+156.48%
|
-270.87
-165.79%
|
411.74
+1208.84%
|
31.46
|
| Effect Of Exchange Rate Changes |
|
1.11
+766.41%
|
0.13
+268.42%
|
-0.08
-989.93%
|
0.01
|
| Beginning Cash Position |
|
180.43
-60.01%
|
451.17
+1042.03%
|
39.51
+391.44%
|
8.04
|
| End Cash Position |
|
334.52
+85.40%
|
180.43
-60.01%
|
451.17
+1042.04%
|
39.51
|
| Free Cash Flow |
|
-196.04
-67.40%
|
-117.11
-171.95%
|
-43.06
+22.98%
|
-55.91
|
| Interest Paid Supplemental Data |
|
5.06
|
0.00
|
0.00
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
0.15
+253.11%
|
0.04
+867.37%
|
0.00
|
| Common Stock Issuance |
|
72.39
+37.79%
|
52.54
-89.11%
|
482.45
|
0.00
|
| Issuance Of Capital Stock |
|
72.39
+37.79%
|
52.54
-89.11%
|
482.45
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-05-13 View
- 10-Q2026-05-11 View
- 8-K2026-05-11 View
- 42026-04-16 View
- 42026-04-14 View
- 42026-04-10 View
- 42026-04-02 View
- 10-K2026-02-25 View
- 8-K2026-02-23 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 8-K2026-01-08 View
- 42025-12-22 View
- 42025-12-22 View
- 42025-12-22 View
- 42025-12-10 View
- 42025-12-10 View
- 8-K2025-11-05 View
- 10-Q2025-11-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|